http://www.acc.org/latest-in-cardiology/articles/2018/03/05/15/53/sat-9am-odyssey-outcomes-cv-outcomes-with-alirocumab-after-acs-acc-2018

It looks like diminishing returns but they were able to show a cv outcome benefit in this study.

Still room for RVX to work on residual risk.

The LDL hypothesis does not explain all cv risk.

bfw